TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38770804

Group type: EXPERIMENTAL
Intervention: Cessation counselling
Number of subjects: 42273

Group type: COMPARATOR
Intervention: Counselling interventions of less intensity or shorter duration
Number of subjects: 42273

Group type: EXPERIMENTAL
Intervention: Counselling for at least 15 minutes in the hospital
Number of subjects: 42273

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Number of subjects: 42273

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 42273

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 42273

Group type: EXPERIMENTAL
Intervention: Counselling and pharmacotherapy after discharge
Number of subjects: 42273

Group type: COMPARATOR
Intervention: Post-discharge interventions offering real-time counselling without pharmacotherapy
Number of subjects: 42273

Group type: COMPARATOR
Intervention: Telephone quitlines
Number of subjects: 42273
Study: 38770818

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors
Number of subjects: 65241
Study: 38771012

Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38771081

Group type: EXPERIMENTAL
Intervention: Acute surgery performed in 99/461 patients (21%)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Larger EDH volumes
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Smaller ASDH volumes
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Midline shift
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Between-site variation
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Six-month Glasgow Outcome Scale-Extended scores ≥5
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Mortality rate
Number of subjects: 461
Study: 38771152

Group type: EXPERIMENTAL
Intervention: 30 mg of curcuminoids in turmeric extract capsules and acupressure (group 1)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo and sham acupressure (group 2)
Number of subjects: 72
Study: 38771379

Group type: EXPERIMENTAL
Intervention: para-chloro-2-
Number of subjects: 0
Study: 38771460

Group type: EXPERIMENTAL
Intervention: Four-point scleral fixation (Akreos AO60)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Yamane technique (AcrySof MA60AC)
Number of subjects: 50
Study: 38771467

Group type: EXPERIMENTAL
Intervention: Ketotifen (1 mg twice daily for 4 weeks)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 38771476

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of Candesartan Cilexetil/Amlodipine/Atorvastatin (16/10/40 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of Candesartan Cilexetil/Amlodipine/Atorvastatin (16/5/20 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual formulations of Candesartan Cilexetil, Amlodipine, and Atorvastatin
Number of subjects: 0
Study: 38771490

Group type: EXPERIMENTAL
Intervention: PEEP 5 cmH2O
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: PEEP 10 cmH2O
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: PEEP 15 cmH2O
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Overall RRI during PEEP trial
Number of subjects: 92
Study: 38771499

Group type: EXPERIMENTAL
Intervention: ropeginterferon-alfa2b (ropegIFNα2b)
Number of subjects: 149
Study: 38771622

Group type: EXPERIMENTAL
Intervention: User-Centered Framework for Implementation of Technology (UFIT)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Improving Pediatric Obesity Practice Using Prompts (integrated package comprising CDS for obesity treatment)
Number of subjects: 41
Study: 38771808

Group type: EXPERIMENTAL
Intervention: Aortic Valve Improved Treatment Approaches (AVITA), an interactive, online decision aid
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aortic Valve Improved Treatment Approaches (AVITA)
Number of subjects: 30
Study: 38771906

Group type: EXPERIMENTAL
Intervention: Aortic stenosis (AS) patients
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Coexisting AS and transthyretin cardiac amyloidosis
Number of subjects: 199

Group type: COMPARATOR
Intervention: Controls (no significant coronary artery disease or infarction)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Regional differences in ECV
Number of subjects: 199
Study: 38771911

Group type: EXPERIMENTAL
Intervention: μFR >0.80
Number of subjects: 443

Group type: COMPARATOR
Intervention: QFR
Number of subjects: 443

Group type: COMPARATOR
Intervention: FFR
Number of subjects: 443
Study: 38771973

Group type: EXPERIMENTAL
Intervention: Distinct types of therapy activity preferences
Number of subjects: 621

Group type: COMPARATOR
Intervention: No specific therapy activity or preference
Number of subjects: 621
Study: 38771986

Group type: EXPERIMENTAL
Intervention: C7R-GD2.CARTs
Number of subjects: 11

Group type: COMPARATOR
Intervention: GD2.CARTs
Number of subjects: 11
Study: 38771995

Group type: EXPERIMENTAL
Intervention: Ribociclib plus endocrine therapy (ET) (600 mg once daily; 3 weeks on, 1 week off)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Combination chemotherapy (CT) (docetaxel plus capecitabine, paclitaxel plus gemcitabine, or capecitabine plus vinorelbine)
Number of subjects: 222
Study: 38772477

Group type: EXPERIMENTAL
Intervention: Ablative stereotactic body radiation therapy (SBRT) delivered using a risk adaptive approach (50 Gy/5 fractions, 60 Gy/8 fractions, 70 Gy/10 fractions)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ablative stereotactic body radiation therapy (SBRT)
Number of subjects: 32
Study: 38772517

Group type: EXPERIMENTAL
Intervention: Home modifications and self-management training from an occupational therapist over 4 visits in the home
Number of subjects: 183

Group type: COMPARATOR
Intervention: Stroke education (control group)
Number of subjects: 183
Study: 38772577

Group type: EXPERIMENTAL
Intervention: Living alone
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Living alone (older age above median 74.6 years)
Number of subjects: 494
Study: 38772883

Group type: EXPERIMENTAL
Intervention: 240 mg Dimethyl fumarate (DMF) orally every day for 6 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo orally every day for 6 months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 240 mg Dimethyl fumarate (DMF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 38772898

Group type: EXPERIMENTAL
Intervention: ACT intervention (Advance Consultations Concerning your Life and Treatment)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 400
Study: 38772935

Group type: EXPERIMENTAL
Intervention: Medial Sustain Nail (MSN)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Proximal Femoral Nail Antirotation (PFNA)
Number of subjects: 50
Study: 38772998

Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-DOTA-TATE
Number of subjects: 161
Study: 38773008

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Overall CADS
Number of subjects: 256
Study: 38773189

Group type: EXPERIMENTAL
Intervention: PEGPH20 therapy
Number of subjects: 29
Study: 38773199

Group type: EXPERIMENTAL
Intervention: Glycine 0.5 g/kg/day by enteral route
Number of subjects: 56

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 56
Study: 38773224

Group type: EXPERIMENTAL
Intervention: VT1021
Number of subjects: 22
Study: 38773375

Group type: EXPERIMENTAL
Intervention: Atogepant 10, 30, and 60 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atogepant 60 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atogepant treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38773386

Group type: EXPERIMENTAL
Intervention: Bougie-first approach
Number of subjects: 65

Group type: COMPARATOR
Intervention: Preloaded bougie approach
Number of subjects: 65

Group type: COMPARATOR
Intervention: ETT with stylet approach
Number of subjects: 65

Group type: COMPARATOR
Intervention: ETT without stylet approach
Number of subjects: 65
Study: 38773408

Group type: EXPERIMENTAL
Intervention: Overall and fitness-specific METs intensity thresholds derived for older adults.
Number of subjects: 93
Study: 38773430

Group type: EXPERIMENTAL
Intervention: Enhanced patient-reported outcomes (PROs) including LURN Symptom Index (SI)-29 and AUA-SI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Routine clinical tests integrated with PRO assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychometric properties of the LURN SIs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Care-coordination recommendations based on PROs
Number of subjects: 0
Study: 38773457

Group type: EXPERIMENTAL
Intervention: Preoperative concurrent chemoradiotherapy (preCRT) with raltitrexed (3 mg/m2 on days 1 and 22) and radiotherapy (50 Gy)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Preoperative concurrent chemoradiotherapy (preCRT)
Number of subjects: 68
Study: 38773528

Group type: EXPERIMENTAL
Intervention: Primaquine (PQ) 0.4-0.5 mg/kg
Number of subjects: 28
Study: 38773543

Group type: EXPERIMENTAL
Intervention: Very low-energy diets (VLEDs); specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified; details not available.
Number of subjects: 0
Study: 38773552

Group type: EXPERIMENTAL
Intervention: Infrared laser moxibustion (ILM)
Number of subjects: 140
Study: 38773563

Group type: EXPERIMENTAL
Intervention: guselkumab Q4W
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: guselkumab Q8W
Number of subjects: 450

Group type: COMPARATOR
Intervention: placebo→guselkumab Q4W (at Week 24)
Number of subjects: 450
Study: 38773568

Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation programme (Rehab2Life)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 38773593

Group type: EXPERIMENTAL
Intervention: High-resolution computed tomography (HRCT) scan
Number of subjects: 1200
Study: 38773595

Group type: EXPERIMENTAL
Intervention: 4-aminopyridine (4AP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 38773608

Group type: EXPERIMENTAL
Intervention: Telemetric ICP sensor measurement in supine position
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telemetric ICP sensor measurement in upright standing position
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telemetric ICP sensor measurement in lateral recumbent position
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telemetric ICP sensor measurement in 45-degree sitting position
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICP measurements at day 1, 14, 30, and 90 following surgery
Number of subjects: 0
Study: 38773643

Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy (SRT) treatment (24 Gy, single fraction)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment (continuation of anti-seizure medication and neuromodulation)
Number of subjects: 0
Study: 38773653

Group type: EXPERIMENTAL
Intervention: Intravenous 2% lidocaine bolus of 1.5 mg/kg with induction of anesthesia, followed by a 2.0 mg/kg/h infusion until the end of surgery
Number of subjects: 1602

Group type: COMPARATOR
Intervention: Placebo solution (normal saline) at the same volume
Number of subjects: 1602

Group type: EXPERIMENTAL
Intervention: Intravenous 2% lidocaine
Number of subjects: 1602

Group type: COMPARATOR
Intervention: Placebo solution (normal saline)
Number of subjects: 1602
Study: 38773658

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) device use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Periodic glucose monitoring (CGM) device use
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 38773662

Group type: EXPERIMENTAL
Intervention: Telemedicine home-based management program including support from a nursing case manager, daily physical activity stimulation, teleconsultations, telemonitoring, and an app for monitoring clinical parameters.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine care (Control group).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telemedicine home-based management program.
Number of subjects: 0
Study: 38773832

Group type: EXPERIMENTAL
Intervention: Comorbidity
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Operative time >180 minutes
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Extracorporeal anastomosis
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Overall surgical site infection
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Incisional surgical site infection
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Organ/space surgical site infection
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Side-to-side anastomosis
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Conversion to open surgery
Number of subjects: 995
Study: 38774010

Group type: EXPERIMENTAL
Intervention: Tafamidis (20 mg and 80 mg pooled)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38774037

Group type: EXPERIMENTAL
Intervention: Extended-release once-nightly sodium oxybate (ON-SXB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38774367

Group type: EXPERIMENTAL
Intervention: PPG-guided algorithm for blood pressure measurement
Number of subjects: 97

Group type: COMPARATOR
Intervention: Cuff-based initialization measurements
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: PPG-based BP algorithm
Number of subjects: 97
Study: 38774370

Group type: EXPERIMENTAL
Intervention: Voice-assisted technology (Amazon Alexa) for SARS-CoV2 screening questionnaire
Number of subjects: 52

Group type: COMPARATOR
Intervention: Healthcare personnel for SARS-CoV2 screening questionnaire
Number of subjects: 52
Study: 38774377

Group type: EXPERIMENTAL
Intervention: Digital recruitment and screening for atrial fibrillation
Number of subjects: 10582
Study: 38774381

Group type: EXPERIMENTAL
Intervention: Consumer wearable device (wrist-worn) monitoring heart rate (HR) using photoplethysmography (PPG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Implantable loop recorder (ILR)
Number of subjects: 0
Study: 38774417

Group type: EXPERIMENTAL
Intervention: CEUS LR-5
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: EOB-MRI LR-5
Number of subjects: 119

Group type: COMPARATOR
Intervention: CEUS and EOB-MRI
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: New criteria (CEUS LR-5 and EOB-MRI LR-4/5 or CEUS LR-4/5 and EOB-MRI LR-5)
Number of subjects: 119
Study: 38774425

Group type: EXPERIMENTAL
Intervention: Direct factor Xa inhibitors (apixaban, edoxaban, rivaroxaban)
Number of subjects: 0
Study: 38774484

Group type: EXPERIMENTAL
Intervention: Intranasal remimazolam 1.5mg/kg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 90
Study: 38774675

Group type: EXPERIMENTAL
Intervention: BCG-Denmark (single 0.1 ml intradermal injection)
Number of subjects: 6828

Group type: COMPARATOR
Intervention: Control (no BCG)
Number of subjects: 6828
Study: 38774780

Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) therapy for 9 weeks
Number of subjects: 13
Study: 38775072

Group type: EXPERIMENTAL
Intervention: Serum progesterone (P) levels measured at 08:00h, 12:00h, 16:00h, and 20:00h on the day of FET.
Number of subjects: 22
Study: 38775119

Group type: EXPERIMENTAL
Intervention: MDR + EGE
Number of subjects: 251

Group type: COMPARATOR
Intervention: EGE only
Number of subjects: 251
Study: 38775162

Group type: EXPERIMENTAL
Intervention: Family-based eHealth intervention (up to three sessions)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Standard medical care control group
Number of subjects: 149
Study: 38775253

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of loop diuretics
Number of subjects: 681

Group type: COMPARATOR
Intervention: Bolus injection of loop diuretics
Number of subjects: 681
Study: 38775255

Group type: EXPERIMENTAL
Intervention: Vitamin C (1400 mg) plus vitamin E (800 mg)
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: Zinc
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1200 mg
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: Omega-3
Number of subjects: 1609
Study: 38775275

Group type: EXPERIMENTAL
Intervention: Direct-to-participant methods for remote enrollment and follow-up
Number of subjects: 5598

Group type: EXPERIMENTAL
Intervention: Weekly surveys and biweekly nasal sampling
Number of subjects: 5598

Group type: EXPERIMENTAL
Intervention: Longitudinal sampling of host nasal transcriptome
Number of subjects: 5598
Study: 38775299

Group type: EXPERIMENTAL
Intervention: Slow dialysis
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Standard sodium dialysate
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sodium modelling
Number of subjects: 32

Group type: COMPARATOR
Intervention: High sodium dialysate
Number of subjects: 32
Study: 38775302

Group type: EXPERIMENTAL
Intervention: Zanubrutinib (Bruton tyrosine kinase inhibitor); specific dosage and duration not mentioned.
Number of subjects: 0
Study: 38775310

Group type: EXPERIMENTAL
Intervention: Cold Snare Polypectomy (CSP)
Number of subjects: 386

Group type: COMPARATOR
Intervention: Hot Snare Polypectomy (HSP)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Cold Snare Polypectomy (CSP) with IPPB
Number of subjects: 386
Study: 38775331

Group type: EXPERIMENTAL
Intervention: Own oocytes - PGT-A analyzed embryos
Number of subjects: 3741

Group type: COMPARATOR
Intervention: Own oocytes - Untested embryos
Number of subjects: 3741

Group type: EXPERIMENTAL
Intervention: Own oocytes - pET-ERA analyzed embryos
Number of subjects: 3741

Group type: EXPERIMENTAL
Intervention: Own oocytes - PGT-A + pET-ERA analyzed embryos
Number of subjects: 3741

Group type: EXPERIMENTAL
Intervention: Donated oocytes - PGT-A analyzed embryos
Number of subjects: 3741

Group type: EXPERIMENTAL
Intervention: Donated oocytes - pET-ERA analyzed embryos
Number of subjects: 3741

Group type: COMPARATOR
Intervention: Donated oocytes - Untested embryos
Number of subjects: 3741

Group type: EXPERIMENTAL
Intervention: Donated oocytes - PGT-A + pET-ERA analyzed embryos
Number of subjects: 3741
Study: 38775618

Group type: EXPERIMENTAL
Intervention: Robotic gastrectomy (RG)
Number of subjects: 527
Study: 38775632

Group type: EXPERIMENTAL
Intervention: Individually tailored oral health intervention provided by a dental hygienist focusing on oral hygiene and self-care.
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 174
Study: 38775637

Group type: EXPERIMENTAL
Intervention: Belimumab (BEL)
Number of subjects: 1245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1245
Study: 38775645

Group type: EXPERIMENTAL
Intervention: Pedicled technique
Number of subjects: 165

Group type: COMPARATOR
Intervention: Surgical skeletonized technique
Number of subjects: 165

Group type: COMPARATOR
Intervention: Skeletonized with Thunderbeat
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: All techniques
Number of subjects: 165
Study: 38775718

Group type: EXPERIMENTAL
Intervention: irinotecan-cetuximab
Number of subjects: 102

Group type: COMPARATOR
Intervention: modified ramucirumab (irinotecan-cetuximab with ramucirumab)
Number of subjects: 102
Study: 38775857

Group type: EXPERIMENTAL
Intervention: Fluid balance management during the initial 8 days post-aSAH
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Fluid balance
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Transfusion
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Fluid overload
Number of subjects: 237
Study: 38775910

Group type: EXPERIMENTAL
Intervention: Fixed-Dose Combination Product (FDCP) of amlodipine, losartan, ezetimibe, and rosuvastatin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Individual tablets of amlodipine, losartan, ezetimibe, and rosuvastatin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fixed-Dose Combination Product (FDCP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Individual products
Number of subjects: 60
Study: 38775922

Group type: EXPERIMENTAL
Intervention: Beam walking on 8-cm wide beam
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Beam walking on 4-cm wide beam
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Beam walking under single and dual-task conditions
Number of subjects: 196
Study: 38775925

Group type: EXPERIMENTAL
Intervention: Fezolinetant 30 mg
Number of subjects: 1022

Group type: EXPERIMENTAL
Intervention: Fezolinetant 45 mg
Number of subjects: 1022

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1022
Study: 38775927

Group type: EXPERIMENTAL
Intervention: Bovine colostrum (BC)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Conventional fortifier
Number of subjects: 229
Study: 38776067

Group type: EXPERIMENTAL
Intervention: Sacrocolpopexy
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Transvaginal mesh
Number of subjects: 376

Group type: COMPARATOR
Intervention: Native tissue repair
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: All surgeries
Number of subjects: 376
Study: 38776097

Group type: EXPERIMENTAL
Intervention: Dual DCCV (200 J using 2 sets of pads)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Single DCCV (200 J using 1 set of pads)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Single DCCV (200 J using 1 set of pads) after failure
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Dual DCCV and Single DCCV
Number of subjects: 200
Study: 38776275

Group type: EXPERIMENTAL
Intervention: Cerliponase alfa
Number of subjects: 23
Study: 38776307

Group type: EXPERIMENTAL
Intervention: Home-based exercise program (aerobic and resistance exercise) over 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched individuals without T1D (control group)
Number of subjects: 0
Study: 38776334

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy
Number of subjects: 1373
Study: 38776391

Group type: EXPERIMENTAL
Intervention: BNT142 RNA-LNP (0.1- to 1-μg dose range)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BNT142 RNA-LNP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RiboMab02.1
Number of subjects: 0
Study: 38776446

Group type: EXPERIMENTAL
Intervention: Parosmia
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Phantosmia
Number of subjects: 250